首页> 外文OA文献 >CLINICAL EQUIVALENCE OF EVOLOCUMAB 140 MG EVERY TWO WEEKS AND 420 MG MONTHLY DOSING REGIMENS: A POOLED ANALYSIS OF 3146 PATIENTS IN PHASE 3 STUDIES

【2h】

CLINICAL EQUIVALENCE OF EVOLOCUMAB 140 MG EVERY TWO WEEKS AND 420 MG MONTHLY DOSING REGIMENS: A POOLED ANALYSIS OF 3146 PATIENTS IN PHASE 3 STUDIES

机译：每两周服用EVOLOCUMAB 140 MG和每月一次服用MG 420 MG的临床等效性：在第3阶段研究中对3146例患者进行了分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Stein Evan A.; Koren Michael; Honarpour Narimon; Kurtz Christopher; Yang Jingyuan; Wasserman Scott; Raal Frederick;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis [J] . He Xiao-Xiao, Zhang Rong, Zuo Pei-Yuan, European journal of internal medicine . 2017,第期

机译：Evolocumab（AMG 145）在高胆固醇血症患者中每2周给药时每2周为420毫克给药的疗效优势为每2周，每4周为420毫克：来自META分析的证据
2. Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies [J] . Erik Stroes, Jennifer G. Robinson, Frederick J. Raal, Clinical cardiology. . 2018,第10期

机译：PROFICIO患者亚组中evolocumab的LDL-C反应一致：来自3期研究的3146名患者的汇总分析
3. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: The EXTEND study [J] . GalleJ.-C., ClaesK., KissI., Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association . 2012,第6期

机译：一项长期观察性队列研究，对未经透析的慢性肾脏病患者使用达比泊汀α延长剂量（每2周一次或每月一次）方案：EXTEND研究
4. The clinical cohort study on prospective efficacy of CHD Therapeutic Regimen of “the regulation of Pi(Spleen) and protection of Xin(Heart)” method treating CHD patients [C] . Danping Xu, Xia Wang, Wenjie Luo, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：“ Pi（脾）的调节和心（心）的保护”法治疗冠心病的冠心病治疗方案前瞻性临床队列研究
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies [O] . Erik Stroes, Jennifer G. Robinson, Frederick J. Raal, 2018

机译：PROFICIO患者亚组中evolocumab与LDL-C的反应一致：来自3期研究的3146名患者的汇总分析
7. CLINICAL EQUIVALENCE OF EVOLOCUMAB AMONG PATIENT SUBGROUPS IN PROFICIO: A POOLED ANALYSIS OF 3146 PATIENTS FROM PHASE 3 STUDIES [O] . E. Stroes, J. Robinson, F. Raal, 2015

机译：PROFICIO患者亚组中Evolocumab的临床当量：3146阶段研究患者的汇总分析

CLINICAL EQUIVALENCE OF EVOLOCUMAB 140 MG EVERY TWO WEEKS AND 420 MG MONTHLY DOSING REGIMENS: A POOLED ANALYSIS OF 3146 PATIENTS IN PHASE 3 STUDIES

著录项

相似文献

相关主题

期刊订阅